CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 62 filers reported holding CATALYST PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2019 | $196,000 | +232.2% | 51,024 | +339.0% | 0.01% | +175.0% |
Q1 2019 | $59,000 | -65.5% | 11,624 | -87.0% | 0.00% | -63.6% |
Q4 2018 | $171,000 | +108.5% | 89,281 | +307.2% | 0.01% | +175.0% |
Q3 2018 | $82,000 | -68.7% | 21,926 | -80.1% | 0.00% | -63.6% |
Q1 2018 | $262,000 | -61.8% | 109,954 | -37.4% | 0.01% | -63.3% |
Q4 2017 | $686,000 | +251.8% | 175,564 | +126.8% | 0.03% | +200.0% |
Q3 2017 | $195,000 | +473.5% | 77,407 | +523.9% | 0.01% | +400.0% |
Q2 2017 | $34,000 | -65.7% | 12,407 | -75.8% | 0.00% | -60.0% |
Q1 2017 | $99,000 | +50.0% | 51,207 | -19.1% | 0.01% | +25.0% |
Q4 2016 | $66,000 | -25.8% | 63,300 | -49.9% | 0.00% | 0.0% |
Q2 2016 | $89,000 | -66.2% | 126,289 | -44.0% | 0.00% | -66.7% |
Q1 2016 | $263,000 | +220.7% | 225,528 | +568.7% | 0.01% | +200.0% |
Q4 2015 | $82,000 | -79.4% | 33,728 | -63.4% | 0.00% | -71.4% |
Q1 2015 | $398,000 | +272.0% | 92,100 | +155.5% | 0.01% | +250.0% |
Q4 2014 | $107,000 | -48.1% | 36,042 | -41.9% | 0.00% | -60.0% |
Q3 2014 | $206,000 | – | 62,081 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANAKA CAPITAL MANAGEMENT INC | 589,883 | $590,000 | 1.38% |
Broadfin Capital, LLC | 8,200,000 | $8,610,000 | 0.96% |
Avoro Capital Advisors LLC | 1,141,149 | $1,198,000 | 0.24% |
CORRADO ADVISORS, LLC | 190,600 | $200,000 | 0.12% |
Baker Brothers Advisors | 5,102,153 | $5,357,000 | 0.05% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 756,311 | $794,000 | 0.04% |
Point72 Asset Management, L.P. | 2,272,816 | $2,386,000 | 0.02% |
AGRAN LIBBIE | 44,000 | $46,000 | 0.01% |
COMPTON CAPITAL MANAGEMENT INC /RI | 10,000 | $11,000 | 0.01% |
KENNEDY CAPITAL MANAGEMENT LLC | 233,171 | $245,000 | 0.00% |